Pharma's Market

SPECIAL REPORT

Healthy Horizons
A brand new series of weekly segments which will explore the macro and micro issues facing the global economy.

LATEST FROM OUR BLOGS

» More

- Portfolio Prep for Next Week: 'Don't Get Crazy'

MORE HEADLINES

» Markets | Economy | Companies

- Fed Audit Would Hurt Economic Prospects: Bernanke

PHARMA'S MARKET VIDEO

» More

Sebelius on Vaccines

24 Nov 2009

Discussing whether a new $487M investment from the government will help speed up the production of the most important vaccines, with Kathy Sebelius, Health & Human Services secretary and CNBC's Mike Huckman.

The New Formula for Faster Vaccines

24 Nov 2009

Novartis is opening on Tuesday the country's first plant to produce flu vaccines using cell cultures. These vaccines are faster, better and cheaper to make than egg-based methods, reports CNBC's Mike Huckman.

Novartis Opens 1st US Plant for Flu Vaccine

24 Nov 2009

Cholesterol Drug Battle: Niaspan vs. Zetia 16 Nov 2009
Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. CNBC's Mike Huckman has the details.

Cardiologist Grades Cholesterol Drug Study

16 Nov 2009

Abbott Laboratories' Niaspan beat Merck's Zetia in a new study. Dr. Steven Nissen, chairman of the Department of Cardiovascular Medicine at The Cleveland Clinic, shares his reaction with CNBC's Mike Huckman.

Merck's Cholesterol Drugs Under Pressure

16 Nov 2009

A new study is putting Merck's cholesterol drugs under pressure today, reports CNBC's Mike Huckman, with Ken Frazier, Merck Global Human Health president.

RSS FEED

» Help

Subscribe to this RSS feed
Stay up to date with Pharma's Market.

CNBC ON DIGG

Why The Market's Up, But Merck's Down

Published: Thursday, 29 Oct 2009 | 3:16 PM ET

Text Size

By: Mike Huckman
CNBC Correspondent

On a day when the market is in full-tilt rally mode on the GDP number, shares of Dow component Merck [MRK Loading... () ] and the company it's buying, Schering-Plough [SGP Loading... () ], are sliding. So, what gives?

Well, Bernstein analyst Dr. Tim Anderson put out a MRK-SGP research note this morning titled, "Caveat Emptor," and he did a voicemail blast to clients this morning saying he was "sounding the alarm bells once again."

He's writing and talking about the upcoming presentation of data from a study called "Arbiter 6" comparing MRK and SGP's cholesterol-fighter Zetia to Niaspan from Abbott Labs [ABT Loading... () ]. Zetia is also used to make Vytorin along with the statin Zocor. They're big-selling drugs. Researchers will unveil the study results in a so-called "late-breaking clinical trial" session at the American Heart Association's annual meeting in Orlando on Monday, November 16th, at 10:45 a.m. ET. A "late breaker" is prominent, prestigious status that scientific and medical meetings typically grant to big, important studies. They're often done in the biggest convention hall before the largest audience.

Dr. Anderson also says the study will be published simultaneously in a major medical journal, most likely the "New England Journal of Medicine," along with an editorial or two. And he says one of the opinion pieces will be "pretty scathing by a well-known critic." Any guesses? Hmm, lemme think.

Dr. Anderson doesn't think there's anything, as he put it, "truly wrong" with Zetia or Vytorin, but for whatever reason he believes the drugs are "being attacked by some pretty fierce critics." Long-term he still likes Merck together with Schering, but in the near-term he says, "Buyer beware."

On Merck's most recent conference call company officials were already revving up the spin machine. They promised that they will be at AHA in full force messaging docs, so-called key opinion leaders and, of course, the media. I wonder if they'll send the big guns to talk to us.

Disclosures: Someone who lives with one of the Bernstein pharma researchers owns Merck stock. And a part of Bernstein owns at least one percent of MRK and SGP shares.

Questions? Comments? and follow me on Twitter at mhuckman